Evidence map›Paper›PMID 38791353›Full record

ReviewInternational journal of molecular sciences2024

Cholinergic Mechanisms in Gastrointestinal Neoplasia.

Natalia Sampaio Moura, Alyssa Schledwitz, Madeline Alizadeh, Asha Kodan, Lea-Pearl Njei, Jean-Pierre Raufman

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Cancer and neurotransmitter receptors.Chinese medical journal · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Natalia Sampaio MouraDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-8429-5816
Alyssa SchledwitzDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-4288-5551
Madeline AlizadehThe Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0001-5650-3393
Asha KodanDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Lea-Pearl NjeiDepartment of Biological Science, University of Maryland, Baltimore County, Baltimore, MD 21250, USA.ORCID 0000-0002-0787-3045
Jean-Pierre RaufmanDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.ORCID 0000-0002-6340-4382

Funding

Research Training in Gastroenterology and HepatologyT32DK067872 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI RAUFMAN, JEAN-PIERRE · 2005 to 2024
$7.2M
BLRD VA I01 BX002129NIDDK NIH HHS T32 DK067872
6 · The paper itself

Abstract

Acetylcholine-activated receptors are divided broadly into two major structurally distinct classes: ligand-gated ion channel nicotinic and G-protein-coupled muscarinic receptors. Each class encompasses several structurally related receptor subtypes with distinct patterns of tissue expression and post-receptor signal transduction mechanisms. The activation of both nicotinic and muscarinic cholinergic receptors has been associated with the induction and progression of gastrointestinal neoplasia. Herein, after briefly reviewing the classification of acetylcholine-activated receptors and the role that nicotinic and muscarinic cholinergic signaling plays in normal digestive function, we consider the mechanics of acetylcholine synthesis and release by neuronal and non-neuronal cells in the gastrointestinal microenvironment, and current methodology and challenges in measuring serum and tissue acetylcholine levels accurately. Then, we critically evaluate the evidence that constitutive and ligand-induced activation of acetylcholine-activated receptors plays a role in promoting gastrointestinal neoplasia. We focus primarily on adenocarcinomas of the stomach, pancreas, and colon, because these cancers are particularly common worldwide and, when diagnosed at an advanced stage, are associated with very high rates of morbidity and mortality. Throughout this comprehensive review, we concentrate on identifying novel ways to leverage these observations for prognostic and therapeutic purposes.

Indexed as

AcetylcholineGastrointestinal NeoplasmsAnimalsHumansReceptors, MuscarinicReceptors, NicotinicSignal TransductionAcetylcholineReceptors, MuscarinicReceptors, Nicotinicacetylcholinebrain–gut axiscancercellular signalinggastrointestinal cancermuscarinic receptorsnicotinic receptorsprotein kinases

Identifiers

PMID38791353
PMCPMC11120676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.